TOKYO, Mar 11 (Pulse News Wire) – Convano Inc. (6574.T) announced today that its subsidiary, Synk Health Care Co., Ltd., will begin preconsultation with PMDA for approval of a medical hyaluronic acid (HA) product.
The preconsultation, set to commence on April 9, 2026, aims to enhance the precision and reliability of data gaps, quality management systems, and safety assurance requirements prior to formal application submission. This strategic move follows Convano's initial plan outlined on July 31, 2025, which anticipated a February 2026 launch. However, the company decided to prioritize thoroughness over speed to ensure robust evidence and high-quality standards for the product.
As a result, the expected launch date was revised to March 2028. Despite the delay, Convano believes this approach will strengthen their competitive position post-approval, enabling premium pricing and sustained market penetration in the free treatment sector. The company projects that existing sales of higher-priced HA products will offset any near-term revenue impact, maintaining overall performance expectations for the fiscal year ending March 2026.
🔴 Confidence: Review recommended AI-translated content.